Medical tests

QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Tuesday, May 25, 2021
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Science, Oncology, Lung cancer, KRAS, Medical tests, Health, Medicine, Qiagen, Non-small-cell lung carcinoma, Clinical medicine, Cancer, Companion diagnostic, Oncology

The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer (NSCLC), and allows for further development of tests for other Mirati oncology programs.

Key Points: 
  • The agreement initially focuses on a companion diagnostic test for non-small cell lung cancer (NSCLC), and allows for further development of tests for other Mirati oncology programs.
  • QIAGEN and Mirati have previously partnered for the development of a companion diagnostic.
  • We are pleased Mirati recognizes the success of QIAGENs therascreen platform and continues to partner with us to develop a tissue-based companion diagnostic to identify patients who may benefit from adagrasib.
  • The therascreen-based companion diagnostic detects KRASG12C, a genetic mutation that is one of the most common KRAS alterations linked to cancer.

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Medical genetics, Medicine, Clinical medicine, Medical tests, Microarrays, Genetic counseling, Cancer, Genetic testing, Colorectal cancer, Invitae

A separate study of prostate cancer patients confirmed similar findings in other cancer types that limiting testing deprives patients and clinicians of actionable information.

Key Points: 
  • A separate study of prostate cancer patients confirmed similar findings in other cancer types that limiting testing deprives patients and clinicians of actionable information.
  • In a review of two independent datasets, including commercially insured and Medicare Advantage enrollees, only 3% (n=1,675) of the 55,595 colorectal cancer patients received germline genetic testing, despite medical policy recommending germline genetic testing for all colorectal cancer patients (consistent with the INTERCEPT colorectal cancer study ).
  • These data presented at ASCO highlight the need for oncologists to embrace germline genetic testing as routine practice for all cancer patients," said Robert Nussbaum, M.D., chief medical officer at Invitae.
  • Invitae also provides patients direct access to genetic counselors, helping to integrate routine genetic testing into patient care with GIA, a HIPAA-compliant chatbot.

Global WholeHealth Partners Corp (OTC: GWHP) and AAJ has Partnered Together and Agreed to Open a Facility in the Philippines Under the Name Global Wholehealth Philippines, as Filed in 8k on May 21, 2021

Retrieved on: 
Tuesday, May 25, 2021
Health, Medicine, Zoonoses, Pandemics, Medical tests, COVID-19, Occupational safety and health, Public health, Virus, DiaSorin, COVID-19 testing

Globals WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer is capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Globals WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer is capable of detecting all the current identified SARS-CoV-2 viruses.
  • Now, with the vaccine, Global is offering one of the largest lines of products to fight this virus.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.
  • Notably, Global offers 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

Outlook on the Blood Glucose Test Strips Global Market to 2026 - COVID-19 Pandemic Increasing Demand for Test Strips & Lancets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Diabetes, Health, Medical Supplies, Diabetes, Blood tests, Medicine, Medical tests, Clinical medicine, Medical monitoring, Blood glucose monitoring, Blood sugar level, Glucose, Test strip, Glucose meter

The "Blood Glucose Test Strips Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Glucose Test Strips Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global blood glucose test strips market by revenue is expected to grow at a CAGR of over 6% during the period 2020-2026.
  • However, the impact of COVID-19 is not expected to have a long-term effect on the glucose monitoring test strips market.
  • The following factors are likely to contribute to the growth of the blood glucose test strips market during the forecast period:
    The study considers the global blood glucose test strips market's present scenario and its market dynamics for the period 2020-2026.

Global Rapid Antigen Detection Tests Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Medical Supplies, Health, Branches of biology, Biology, Life sciences, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test

The "Rapid Antigen Detection Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rapid Antigen Detection Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Rapid Antigen Detection Tests estimated at US$199.9 Million in the year 2020, is projected to reach a revised size of US$355.9 Million by 2027, growing at a CAGR of 8.6% over the period 2020-2027.
  • The U.S. Market is Estimated at $54 Million, While China is Forecast to Grow at 13% CAGR
    The Rapid Antigen Detection Tests market in the U.S. is estimated at US$54 Million in the year 2020.
  • Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 7.7% respectively over the 2020-2027 period.

Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

Retrieved on: 
Monday, May 24, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Medical tests, DecisionDx-UM, Melanoma

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced it will host a ribbon cutting ceremony and reception for national, state and local officials, employees and other members of the community, at its new corporate headquarters on May 25, 2021, from 3:00 p.m. 6:00 p.m. Central time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced it will host a ribbon cutting ceremony and reception for national, state and local officials, employees and other members of the community, at its new corporate headquarters on May 25, 2021, from 3:00 p.m. 6:00 p.m. Central time.
  • At Castle, we are committed to improving the lives of patients with skin cancer and other dermatologic diseases, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Exact Sciences to participate in June investor conferences

Retrieved on: 
Monday, May 24, 2021
Branches of biology, Medicine, Medical specialties, Medical genetics, Medical terminology, Exact Sciences, Medical tests, Cancer screening, Medical diagnosis, Oncotype, Screening

MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Key Points: 
  • MADISON, Wis., May 24, 2021 /PRNewswire/ --Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
  • A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter answers to give people the clarity to take life-changing action, earlier.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

Retrieved on: 
Friday, May 21, 2021
Medical tests, Saliva testing

K-One MediTech To Begin Production of CE approved 15-Minute Antigen Test Solution

Key Points: 
  • Under this Agreement, K-One MediTech will act as the primary manufacturer in Asia to produce the AcuVid\xe2\x84\xa2 COVID-19 Rapid Antigen Saliva Test Kits.
  • Therma Bright will be able to add FDA Emergency Authorization Use (FDA-EUA) and Health Canada (HC) approved kits once regulatory approvals are secured.
  • "\nIn April 2020, immediately following the COVID-19 pandemic global lockdown, Therma Bright and its team of talented scientists began developing its AcuVid\xe2\x84\xa2 COVID-19 Rapid Antigen Saliva Test using lateral flow technology.
  • Now the AcuVid\xe2\x84\xa2 COVID-19 Rapid Antigen Saliva Test Kit is a much simpler, easy-to-use kit that will simplify the process for medical professionals and individuals administering or taking the AcuVid\xe2\x84\xa2 test, but it also has enabled the Company to significantly reduce its cost from the first prototype version.\nThe K-One MediTech development and manufacturing agreement will provide services which include development, designs, concepts, formula, and manufacturing process for Therma Bright\'s new AcuVid\xe2\x84\xa2 Covid-19 Rapid Antigen Saliva Test.

Ortho Clinical Diagnostics to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, May 21, 2021
Medical tests, Ortho Clinical Diagnostics, IVD, Ortho

b"RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world\xe2\x80\x99s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to present in two upcoming investor conferences:\nUBS Virtual Global Healthcare Conference on Monday, May 24, 2021 at 11:00am ET\nGoldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:30pm ET\nInterested parties can access a live webcast and replay of each presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d portion of the Company\xe2\x80\x99s website at https://ir.orthoclinicaldiagnostics.com/ , under the \xe2\x80\x9cEvents\xe2\x80\x9d section.

Key Points: 
  • b"RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world\xe2\x80\x99s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to present in two upcoming investor conferences:\nUBS Virtual Global Healthcare Conference on Monday, May 24, 2021 at 11:00am ET\nGoldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:30pm ET\nInterested parties can access a live webcast and replay of each presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d portion of the Company\xe2\x80\x99s website at https://ir.orthoclinicaldiagnostics.com/ , under the \xe2\x80\x9cEvents\xe2\x80\x9d section.
  • Management will also be hosting individual meetings with investors at both of the conferences.\nOrtho Clinical Diagnostics (Nasdaq: OCDX) is one of the world\xe2\x80\x99s largest pure-play in vitro diagnostics (IVD) companies.\nMore than 800,000 patients across the world are impacted by Ortho\xe2\x80\x99s tests each day.
  • Because Every Test is a Life\xe2\x84\xa2, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable.
  • Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.\nFrom launching the first product to determine Rh+ or Rh- blood type, developing the world\xe2\x80\x99s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.\nThe company is powered by Ortho Care\xe2\x84\xa2, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.\nFor more information, visit Ortho\xe2\x80\x99s website or social media channels: LinkedIn , Twitter , Facebook and YouTube .\n"

eMed Donates 1,000 COVID-19 Rapid Antigen Tests for the Benefit of M-DCPS Students, Teachers and Families

Retrieved on: 
Thursday, May 20, 2021
Medicine, Immunologic tests, Branches of biology, Clinical medicine, Medical terminology, Medical tests, Chromatography, Molecular biology, Rapid antigen test, COVID-19 testing, ELISA, Return to normalcy

"Helping communities in need attain greater access to rapid antigen testing is part of the solution we can all contribute to as we move forward and transition into a post-pandemic \'transformed normal\'.

Key Points: 
  • "Helping communities in need attain greater access to rapid antigen testing is part of the solution we can all contribute to as we move forward and transition into a post-pandemic \'transformed normal\'.
  • "The distribution of these COVID-19 test kits will contribute to the wellbeing of our community and allow us to continue moving toward a sense of normalcy.
  • "This partnership provides an additional resource for supporting our students and families during such difficult times so that they can overcome this pandemic and return to normalcy.
  • We embrace quantitative medicine to deliver prescribed tests and treatments directly to patients, driving better and more cost-effective health outcomes.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/emed-donates-1-000-covid-19-rapi...\n'